Community Resource Center (CRC) is now accepting nominations for the inaugural 2026 CRC Community Impact Awards, honoring individuals, youth, groups or organizations who demonstrate exceptional ...

BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 ...

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...

A tropical low has now formed in the Coral Sea, prompting warnings of heavy rainfall and damaging winds along more than a ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

Forecasters say the tropical low, known as 12U, near Far North Queensland now has a 60 per cent chance of becoming a cyclone ...

Spruce Biosciences, Inc. (Spruce) , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, ...

wList – enhanced Windows file search and directory listing tool. wList offers faster searches, smart file categorization, and ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

New software delivers true client profitability, profit-aware sprint planning, and operational clarity for SEO and ...

Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial da ...